Tests a home vaginal device for pelvic pain from endometriosis

Trial details

Who runs it

Hyivy Health Inc

Trial code

NCT05643131

Record updated

17 September 2025

Original description

This study seeks to address accessible management of endometriosis-associated chronic pelvic pain by evaluating a novel device used in the home. The study is designed as a proof-of-concept single-arm pilot study, and the primary objective is to assess change in overall self-reported pelvic pain in people with endometriosis-associated chronic pelvic pain following the use of the Hyivy intravaginal device.Read full original descriptionShow less

Evaluation of the Hyivy Device as a Non-hormonal Therapy in People With Endometriosis

This study seeks to address accessible management of endometriosis-associated chronic pelvic pain by evaluating a novel device used in the home. The study is designed as a proof-of-concept single-arm pilot study, and the primary objective is to assess change in overall self-reported pelvic pain in people with endometriosis-associated chronic pelvic pain following the use of the Hyivy intravaginal device.

Inclusion: 1.Age ≥ 18 at the time of enrollment; 2.Generally in good health (other than due to endometriosis), at physician's discretion; 3.Diagnosed with endometriosis (clinical, radiologic, or surgical); 4.Diagnosed with chronic pelvic pain (self-reported pain in pelvic area lasting >3 months); 5.VAS for overall pelvic pain ≥ 4 at screening and baseline; 6.Medically managing endometriosis using continuous hormonal medications (i.e., oral contraceptive pills, progesterone only pills, Mirena, GnRH agonists/antagonists) for at least 3 months prior to enrollment; 7.Agrees not to commence any new treatments (medical or physical therapies) for the 12-week intervention period, including hormonal therapies for any medical condition, and complimentary and/or alternative management of surgery for endometriosis and associated chronic pain; 8.Agrees not to undergo pelvic physiotherapy with a trained professional during the study; 9.Agrees to avoid taking non-steroidal anti-inflammatory drugs (e.g., ibuprofen) for 72 hours before Visits 1, 2, and 3; 10.Must have the ability to charge the investigational device; 11.Must be willing and able to insert intravaginal device; 12.Able to understand, comply and consent to protocol requirements and instructions; 13.Able to attend scheduled study visits and complete required investigations.

Exclusion: 3.Any other medical condition or clinical finding giving reasonable suspicion of a disease or condition that contraindicates the use of the investigational product or that may affect the interpretation of the results or leave the patient at high risk from treatment complications, at the discretion of the investigator(s); 4.Any surgery in the past 3 months or anticipates having surgery during the study; 16.Use of any medical devices that may interfere with the investigational device's function, such as pacemakers, ventilators, and ear implants; 1.Chronic pelvic pain thought to be due to a condition other than endometriosis; 2.Diagnosis of premature ovarian insufficiency; 5.Allergy to Hyivy device's materials; 6.Active vaginal infection (e.g. vulvovaginal candidiasis, trichomonas vaginitis, bacterial vaginosis, STIs) or infection in the pelvic area; 7.Current use of antibiotics and a history of vulvovaginal candidiasis; 8.Pregnant or lactating; 9.Currently under the care of a pelvic floor physiotherapist; 10.Have open wounds, cuts, or open sores present in vaginal or pelvic area; 11.Severe atrophic vaginitis or very dry, itchy, or sore vagina/vaginal area, at the discretion of the primary investigator(s); 12.Hypoesthesia or loss in sensation of the pelvic floor; 13.Total and/or partial prolapse of the uterus and/or vagina; 14.Symptoms of severe urinary retention, severe extra-urethral incontinence or overflow incontinence; 15.Unable to position the device according to directions for use.

ClinicalTrials.gov NCT05643131